317 related articles for article (PubMed ID: 23685836)
1. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.
Rosenblatt J; Avivi I; Vasir B; Uhl L; Munshi NC; Katz T; Dey BR; Somaiya P; Mills H; Campigotto F; Weller E; Joyce R; Levine JD; Tzachanis D; Richardson P; Laubach J; Raje N; Boussiotis V; Yuan YE; Bisharat L; Held V; Rowe J; Anderson K; Kufe D; Avigan D
Clin Cancer Res; 2013 Jul; 19(13):3640-8. PubMed ID: 23685836
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
Rosenblatt J; Vasir B; Uhl L; Blotta S; Macnamara C; Somaiya P; Wu Z; Joyce R; Levine JD; Dombagoda D; Yuan YE; Francoeur K; Fitzgerald D; Richardson P; Weller E; Anderson K; Kufe D; Munshi N; Avigan D
Blood; 2011 Jan; 117(2):393-402. PubMed ID: 21030562
[TBL] [Abstract][Full Text] [Related]
3. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study.
Reichardt VL; Okada CY; Liso A; Benike CJ; Stockerl-Goldstein KE; Engleman EG; Blume KG; Levy R
Blood; 1999 Apr; 93(7):2411-9. PubMed ID: 10090953
[TBL] [Abstract][Full Text] [Related]
4. Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.
Chung DJ; Shah N; Wu J; Logan B; Bisharat L; Callander N; Cheloni G; Anderson K; Chodon T; Dhakal B; Devine S; Somaiya Dutt P; Efebera Y; Geller N; Ghiasuddin H; Hematti P; Holmberg L; Howard A; Johnson B; Karagkouni D; Lazarus HM; Malek E; McCarthy P; McKenna D; Mendizabal A; Nooka A; Munshi N; O'Donnell L; Rapoport AP; Reese J; Rosenblatt J; Soiffer R; Stroopinsky D; Uhl L; Vlachos IS; Waller EK; Young JW; Pasquini MC; Avigan D
Clin Cancer Res; 2023 Dec; 29(23):4784-4796. PubMed ID: 37463058
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with dendritic cell-tumor fusion cells in multiple myeloma patients: a promising strategy?
Garcia-Marquez MA; Shimabukuro-Vornhagen A; Theurich S; von Bergwelt-Baildon M
Immunotherapy; 2013 Oct; 5(10):1039-42. PubMed ID: 24088074
[TBL] [Abstract][Full Text] [Related]
6. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
[TBL] [Abstract][Full Text] [Related]
8. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
9. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma.
Liso A; Stockerl-Goldstein KE; Auffermann-Gretzinger S; Benike CJ; Reichardt V; van Beckhoven A; Rajapaksa R; Engleman EG; Blume KG; Levy R
Biol Blood Marrow Transplant; 2000; 6(6):621-7. PubMed ID: 11128812
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients.
Hobo W; Strobbe L; Maas F; Fredrix H; Greupink-Draaisma A; Esendam B; de Witte T; Preijers F; Levenga H; van Rees B; Raymakers R; Schaap N; Dolstra H
Cancer Immunol Immunother; 2013 Aug; 62(8):1381-92. PubMed ID: 23728352
[TBL] [Abstract][Full Text] [Related]
11. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
12. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.
Massaia M; Borrione P; Battaglio S; Mariani S; Beggiato E; Napoli P; Voena C; Bianchi A; Coscia M; Besostri B; Peola S; Stiefel T; Even J; Novero D; Boccadoro M; Pileri A
Blood; 1999 Jul; 94(2):673-83. PubMed ID: 10397734
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
Pyzer AR; Avigan DE; Rosenblatt J
Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination.
Svane IM; Nikolajsen K; Johnsen HE
Scand J Immunol; 2007 Oct; 66(4):465-75. PubMed ID: 17850592
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
16. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
[TBL] [Abstract][Full Text] [Related]
17. Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.
Chung DJ; Sharma S; Rangesa M; DeWolf S; Elhanati Y; Perica K; Young JW
Blood Adv; 2022 Mar; 6(5):1547-1558. PubMed ID: 35100339
[TBL] [Abstract][Full Text] [Related]
18. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
[TBL] [Abstract][Full Text] [Related]
19. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
[TBL] [Abstract][Full Text] [Related]
20. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
